1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone

Authors :: F.S. Hodi
Kenneth F. Grossmann
Céleste Lebbé
Jason Chesney
John Wagstaff
Sandra Re
J.M.G. Larkin
Jessica C. Hassel
Anna C. Pavlick
Georgina V. Long
P.A. Ascierto
C. Robert
Ivan Marquez-Rodas
Jedd D. Wolchok
Marcus O. Butler
W. van Dijck
Michael A. Postow
Oliver Bechter
Dirk Schadendorf
J.-J. Grob
Source :: Annals of Oncology. 31:S734-S735
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Internal medicine
medicine
In patient
Ipilimumab
Hematology
Nivolumab
business
Advanced melanoma
medicine.drug

Tools